Literature DB >> 11328214

The risk of limb deficiencies and other congenital abnormalities in children exposed in utero to calcium channel blockers.

H T Sørensen1, A E Czeizel, M Rockenbauer, F H Steffensen, J Olsen.   

Abstract

AIM: Calcium channel blockers given to pregnant rats have shown an increased prevalence of digital and limb defects and their safety in pregnant women has thus been questioned. We examined the risk of malformations following exposure in utero to calcium channel blockers.
METHOD: We conducted a nationwide case-control study based on the Hungarian Case-Control Surveillance of Congenital Abnormalities and identified 22,865 cases with congenital abnormalities and 31,151 population controls during the period 1980-1996. Data on drug exposure were obtained from official questionnaires and obligatory prenatal care logbooks.
RESULTS: Among the cases, 586 mothers (2.6%) had been exposed to calcium channel blockers during pregnancy compared with 907 controls (2.4%). The overall prevalence ratios for 17 congenital abnormalities varied between 1.1 and 1.4, and there was no significant increased risk of limb deficiencies or other congenital abnormalities.
CONCLUSION: Our data did not indicate an increased prevalence of congenital abnormalities in offspring exposed to calcium channel blockers in utero.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11328214

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  14 in total

1.  Maternal hypertension, medication use, and hypospadias in the National Birth Defects Prevention Study.

Authors:  Alissa R Van Zutphen; Martha M Werler; Marilyn M Browne; Paul A Romitti; Erin M Bell; Louise-Anne McNutt; Charlotte M Druschel; Allen A Mitchell
Journal:  Obstet Gynecol       Date:  2014-02       Impact factor: 7.661

2.  Maternal hypertension with nifedipine treatment associated with a higher risk for right-sided obstructive defects of the heart: a population-based case-control study.

Authors:  Melinda Csáky-Szunyogh; Attila Vereczkey; Balázs Gerencsér; Andrew E Czeizel
Journal:  Heart Asia       Date:  2014-01-23

3.  Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy.

Authors:  Robert L Davis; David Eastman; Heather McPhillips; Marsha A Raebel; Susan E Andrade; David Smith; Marianne Ulcickas Yood; Sascha Dublin; Richard Platt
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-11-15       Impact factor: 2.890

4.  Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations.

Authors:  Alissa R Caton; Erin M Bell; Charlotte M Druschel; Martha M Werler; Angela E Lin; Marilyn L Browne; Louise-Anne McNutt; Paul A Romitti; Allen A Mitchell; Richard S Olney; Adolfo Correa
Journal:  Hypertension       Date:  2009-05-11       Impact factor: 10.190

Review 5.  Headache in pregnancy.

Authors:  Dawn A Marcus
Journal:  Curr Pain Headache Rep       Date:  2003-08

6.  Maternal vasoactive exposures, amniotic bands, and terminal transverse limb defects.

Authors:  Martha M Werler; Jaclyn L F Bosco; Stuart K Shapira
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2009-01

7.  Headache related to pregnancy: management of migraine and migraine headache in pregnancy.

Authors:  Jan Lewis Brandes
Journal:  Curr Treat Options Neurol       Date:  2008-01       Impact factor: 3.598

8.  Fetal safety of calcium channel blockers.

Authors:  Fatoumah Alabdulrazzaq; Gideon Koren
Journal:  Can Fam Physician       Date:  2012-07       Impact factor: 3.275

Review 9.  Maternal Hypertension During Pregnancy and the Risk of Congenital Heart Defects in Offspring: A Systematic Review and Meta-analysis.

Authors:  Anushuya Ramakrishnan; Laura J Lee; Laura E Mitchell; A J Agopian
Journal:  Pediatr Cardiol       Date:  2015-05-08       Impact factor: 1.655

Review 10.  Use of medication for cardiovascular disease during pregnancy.

Authors:  Petronella G Pieper
Journal:  Nat Rev Cardiol       Date:  2015-12       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.